DSMB RECOMMENDS THAT GENITOPE CONTINUE MYVAX STUDY
Genitope announced that its independent data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in its Phase III clinical trial for treatment of follicular non-Hodgkin's lymphoma (NHL) and recommended that the trial continue as planned. The clinical trial will be completed by December 2007.
This trial evaluates the safety and efficacy of the company's lead product candidate, MyVax personalized immunotherapy, in patients with previously untreated NHL. The trial compares patients treated with the drug to patients treated with a nonspecific immunotherapy control.